Evaluation of the antiviral activity of (1’S,2’R)-9-[[1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants.

The research article is about the study on the effectiveness of A-5021 in inhibiting the replication of Equine herpesvirus 1 (EHV1) in horses, a virus that can cause respiratory disease and neurological symptoms.

Objective of the Study

The research was carried out to evaluate the use of A-5021 to treat and prevent instances of EHV1 in horses. A-5021 was previously shown to have effective anti-herpetic activity against most human herpesviruses. The aim was to understand how it performed in the context of EHV1.

Methods Used in the Study

• The team of researchers infected equine embryonic lung (EEL) cells with two separate strains of EHV1 — 97P70, a non-neurovirulent strain, and 03P37, a neurovirulent strain.
• They then treated the infected cells with A-5021, studying the effectiveness of the treatment in inhibiting viral replication.
• The potency of A-5021 was compared with acyclovir, a common antiviral medication.
• The researchers also tested A-5021 in equine nasal mucosal explants to prevent viral plaque formation, a crucial step in preventing the spread of the virus.

Findings of the Study

• The review showed that A-5021, in comparison to acyclovir, was significantly more potent in inhibiting viral replication, approximately 15 times more effective.
• Moreover, in the equine nasal mucosal explants, A-5021 was able to eliminate viral plaque formation entirely at concentrations of 8 and 32μM, whereas acyclovir had no antiviral effect at these concentrations.

Implications of the Findings

• This suggests that A-5021 may have significant potential in treating and preventing EHV1 infections.
• These findings could help shape therapeutics for EHV1, as A-5021 could become an effective treatment for the virus.